Aug 2026· 2026 7th International Conference on Biomedical Engineering and Bioinformatics for Health (ICBEBH)· pp. 1-6· 0 citations· 16 references
Abstract
For driver-negative advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have been established as the standard therapy, but only a few patients can achieve lasting clinical benefits, and reliable non-invasively predictive tools are urgently needed in clinical practice. CT radiomics can non-invasively characterize tumor phenotype and microenvironment information by extracting quantitative features from conventional images, demonstrating great potential in the field of efficacy prediction. The research progress of CT radiomics in forecasting immunotherapy outcomes for NSCLC is systematically reviewed in this paper. Starting from core methodologies such as image acquisition and tumor segmentation, feature extraction and screening, and prediction model construction and validation, it focuses on exploring its clinical applications in predicting persistent clinical benefits, survival outcomes, biomarker expression, and dynamic evaluation of Delta radiomics. The limitations of current research with respect to generalization and biological interpretability, as well as the prospective directions of multimodal fusion and future validation, are finally analyzed and outlined. Such an exposition intends to furnish systematic references for scholars in this field.
Despite advancements in perioperative and consolidative immunotherapy in early-stage to locally advanced non-small cell lung cancer (NSCLC), recurrence rates remain substantial. In this context, liquid biopsy has transformed the oncological landscape by enabling the non-invasive detection of tumor-derived components, i...
Charline Leclercq, M. Wespiser, G. Tachon et al.· Frontiers in Oncology· 0 citations
Although immunotherapy has completely transformed the treatment landscape of nonsmall cell lung cancer (NSCLC), its wide application is still limited by the heterogeneity of patient responses, primary and acquired resistance, as well as the management challenges of immune‐related adverse events (irAEs). To achieve prec...
Yu-Ting Sun, Xue-Lei Chu, Xin-Miao Wang et al.· Thoracic Cancer· 0 citations
High-risk non–muscle invasive bladder cancer poses therapeutic challenges, with significant rates of recurrence and progression with standard intravesical bacillus Calmette-Guérin (BCG) therapy. Current surveillance strategies lack accurate risk stratification models to predict individual treatment response and persona...
Willian Ito, Isamu Tachibana· Therapeutic Advances in Urol...· 0 citations
Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrai...
Shuai-Yu Zheng, Chi Lv, Zhen Yao· Frontiers in Medicine· 0 citations
Current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology are examined and their potential to be incorporated into a proposed multimodal model is examined.
T. Chakrabarti, A. Mansour, Xi-Wei Wu et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.